Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced on July 23, 2026, that it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026. The disclosure will occur after the close of trading, allowing investors to review the data before market open the following day. This filing provides a timeline for the company’s upcoming performance review, which is critical for stakeholders tracking its biopharmaceutical progress.

The company will host a conference call on Thursday, August 6, 2026, at 1:30pm PT/4:30pm ET to discuss the results. Management will use this forum to address questions regarding the quarter’s operational and financial metrics. The event underscores the importance of transparency in communicating Halozyme’s strategic execution and commercial performance to the investment community.

Event Details

Access to the conference call requires pre-registration via the provided link. A live webcast and replay of the call will also be available through the “Investors” section of Halozyme’s corporate website. These digital channels ensure broad accessibility for analysts, shareholders, and media representatives who may not be able to join the live audio bridge.

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids. This technology reduces treatment burden and improves convenience for patients.

ENHANZE has touched more than one million patient lives through ten commercialized products across over 100 global markets. The technology is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte. This extensive licensing network highlights the widespread adoption of Halozyme’s core platform.

Beyond ENHANZE, Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon and Surf Bio’s hyperconcentration technology. Hypercon is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage. This enables administration in at-home and healthcare-provider settings, further broadening the range of biologics that can be delivered subcutaneously.

The Hypercon technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals and Oruka Therapeutics. Additionally, Halozyme develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies. The Company has two proprietary commercial products, Hylenex and XYOSTED, alongside partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

HC Wainwright & Co. analyst Mitchell S. Kapoor has reaffirmed a Buy rating on Halozyme Therapeutics, maintaining a price target of $95. The endorsement signals continued confidence in the biotechnology company's stock performance.

The rating reiteration comes as Halozyme Therapeutics continues to trade on the NASDAQ under the ticker symbol HALO. The $95 price target provides a reference point for investors evaluating the stock's potential upside.

Analyst Details